A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia

Exclusion Criteria

• •1. The patient was diagnosed with acute promyelocytic leukemia or AML BCR-ABL1 positive.
• •2. Active leukemic infiltration of the central nervous system.
• •3. Active infection that is uncontrolled and requires systemic treatment.
• •4. Use of strong inducers of CYP3A4 within 7 days prior to the first dose of the investigational drug, and/or use of moderate to strong inhibitors of CYP3A4 within 7 days or 3-5 half-lives (whichever is longer) prior to the first dose of the investigational drug.
• •5. Previous treatment for hematologic disorders.
• •6. Patients who has a cardiovascular disability status of New York Heart Association Class \> 2.
• •7. Patients have malabsorption syndrome or other conditions that cannot be administered through the gastrointestinal tract or affect drug absorption.
• •8. Patients had a history of other malignancies prior to study initiation.
• •9. Any other circumstances or conditions, at the discretion of the investigator, make the patient unsuitable to participate in the study.